LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

LLY

1,021.56

+3.16%↑

JNJ

229.5

+1.7%↑

ABBV

207.35

-0.79%↓

UNH

402.23

+2.43%↑

AZN

186.64

+0.98%↑

Home・Aktien・Gossamer Bio Inc

Gossamer Bio Inc

Open

BrancheGesundheitswesen

0.34

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.33

Max

0.34

Schlüsselkennzahlen
By Trading Economics
Einkommen	983K -47M
Verkäufe	505K 14M
Gewinnspanne	-342.329
Angestellte	161
EBITDA	-346K -46M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+1261.76% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	14. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-23M 82M
Vorheriger Eröffnungskurs	0.34
Vorheriger Schlusskurs	0.34

Nachrichtenstimmung

By Acuity

79%

21%

322 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

1.06 / 1.23 Unterstützung & Widerstand

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Mai 2026, 22:50 UTC

Ergebnisse

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12. Mai 2026, 22:49 UTC

Ergebnisse

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12. Mai 2026, 22:32 UTC

Ergebnisse

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12. Mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12. Mai 2026, 22:57 UTC

Market Talk

Ergebnisse

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12. Mai 2026, 22:26 UTC

Ergebnisse

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure Interim Dividend A$0.50/Security

12. Mai 2026, 22:24 UTC

Ergebnisse

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12. Mai 2026, 22:19 UTC

Ergebnisse

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA: Business Lending Continued to Grow Above System>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12. Mai 2026, 22:13 UTC

Ergebnisse

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12. Mai 2026, 22:11 UTC

Ergebnisse

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12. Mai 2026, 22:11 UTC

Ergebnisse

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12. Mai 2026, 22:10 UTC

Ergebnisse

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12. Mai 2026, 22:08 UTC

Ergebnisse

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12. Mai 2026, 22:07 UTC

Ergebnisse

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12. Mai 2026, 22:05 UTC

Ergebnisse

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

1261.76% Vorteil

12-Monats-Prognose

Durchschnitt 4.63 USD 1261.76%

Hoch 15 USD

Tief 0.3 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.06 / 1.23Unterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Stimmung

By Acuity

322 / 346 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.